Refine
Has Fulltext
- yes (24)
Is part of the Bibliography
- yes (24)
Year of publication
Document Type
- Journal article (24)
Language
- English (24)
Keywords
- glioblastoma multiforme (6)
- glioblastoma (5)
- recurrence (5)
- astrocytoma (4)
- mRNA (3)
- protein (3)
- relapse (3)
- therapy (3)
- CNS disorders (2)
- MPS1 (2)
- Tumor Treating Fields (TTFields) (2)
- blood–brain barrier (2)
- brain (2)
- expression (2)
- glioma (2)
- low-grade glioma (2)
- organoids (2)
- temozolomide (2)
- vestibular schwannoma (2)
- 3D ex vivo models (1)
- 3D in vitro model (1)
- ADAM9 (1)
- Astrocytic tumor (1)
- Bevacizumab (1)
- Blood–brain barrier (1)
- CNS diseases (1)
- CX3CL1 (1)
- CXCL13 (1)
- CXCR4 (1)
- Expression (1)
- Glioblastom (1)
- Glioblastoma (1)
- Glioblastoma cell line (1)
- Glioblastoma multiforme (1)
- Glioblastomas (1)
- HERV-K (1)
- Human endogenous retrovirus (1)
- IDH (1)
- In vitro models (1)
- Irradiation (1)
- MGMT (1)
- MGMT promoter methylation (1)
- Merlin (1)
- Metalloproteinasen (1)
- Metastatic breast cancer (1)
- N-Myc down regulated gene 1 (1)
- PCDHGC3 (1)
- PCR analysis (1)
- PET/CT (1)
- Pentixafor (1)
- Short dsRNA oligonucleotides (1)
- Spinal dissemination (1)
- Strahlentherapie (1)
- TTFields (1)
- TTK (1)
- Temozolomide (1)
- Tumor-Treating Fields (TTFields) (1)
- WNT signaling (1)
- aging (1)
- anticancer activity (1)
- astrocytic tumor (1)
- behavior (1)
- blood-brain barrier (1)
- brain cancer (1)
- cancer stem cells (1)
- expression pattern (1)
- glioblastoma cell-lines (1)
- glioblastoma multiforme (GBM) (1)
- growth pattern (1)
- human brain microvascular endothelial cells (HBMVEC) (1)
- human cancer diseases (1)
- human cells (1)
- immunofuorescence double staining (1)
- in vitro model (1)
- integrin (1)
- knock down (1)
- liponeurocytoma (1)
- liquid biopsy (1)
- mRNA expression (1)
- matrix metalloproteinase (1)
- mechanism of action (1)
- medulloblastoma (1)
- metastasis (1)
- metastasis-associated in colon cancer 1 (MACC1) (1)
- molecular imaging (1)
- molecular signature (1)
- multifocal growth (1)
- neurocytoma (1)
- non-small cell lung cancer (NSCLC) (1)
- organotypic hippocampal slice cultures (OHSC) (1)
- ovarian cancer (1)
- palladium (1)
- pancreatic cancer (1)
- pathogenesis (1)
- platinum (1)
- primary cell culture (1)
- prognostic marker (1)
- protein and mRNA expression (1)
- radiotherapy (1)
- resistance (1)
- senescence (1)
- slice culture (1)
- suppressor (1)
- taxanes (1)
- therapy response (1)
- thiosemicarbazone (1)
- tumor slice cultures (1)
- tumormicroenvironment (1)
Institute
- Neurochirurgische Klinik und Poliklinik (22)
- Pathologisches Institut (13)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (5)
- Frauenklinik und Poliklinik (3)
- Neurologische Klinik und Poliklinik (2)
- Graduate School of Life Sciences (1)
- Institut für Anatomie und Zellbiologie (1)
- Institut für Anorganische Chemie (1)
- Kinderklinik und Poliklinik (1)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (1)
We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [\(^{68}\)Ga]Pentixafor.
Methods: 4 patients with 6 primarily diagnosed or pre-treated/observed VS were enrolled. All subjects underwent [\(^{68}\)Ga]Pentixafor PET/CT prior to surgical resection. Images were analyzed visually and semi-quantitatively for CXCR4 expression including calculation of tumor-to-background ratios (TBR). Immunohistochemistry served as standard of reference in three patients.
Results: [\(^{68}\)Ga]Pentixafor PET/CT was visually positive in all cases. SUV\(_{mean}\) and SUV\(_{max}\) were 3.0 ± 0.3 and 3.8 ± 0.4 and TBR\(_{mean}\) and TBR\(_{max}\) were 4.0 ± 1.4 and 5.0 ± 1.7, respectively. Histological analysis confirmed CXCR4 expression in tumors.
Conclusion: Non-invasive imaging of CXCR4 expression using [\(^{68}\)Ga]Pentixafor PET/CT of VS is feasible and could prove useful for in vivo assessment of CXCR4 expression.